# ProLynx Reports 12-Week Weight Loss in Rats From One Amylin Agonist Dose at ObesityWeek 2026

> ProLynx presented preclinical data showing a single amylin agonist dose sustained weight loss for 12 weeks in rats, supporting once-quarterly dosing.

- Published: 2026-11-14T17:59:33+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-14/prolynx-obesityweek-amylin-quarterly-dosing
- Source: [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-14-prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides)

## Key takeaways

- ProLynx reported sustained weight loss for 12 weeks in diet-induced obese rats after a single dose of an amylin agonist.
- The company's hydrogel microsphere platform sets peptide half-life through linker chemistry rather than fatty-acid lipidation.
- ProLynx closed a $70 million Series A in December 2025 co-led by 5AM Ventures, OrbiMed and Monograph Capital.

ProLynx reported on November 14, 2026 that a single dose of an amylin agonist sustained weight loss for 12 weeks in rats with diet-induced obesity, data presented at ObesityWeek 2026 in three posters. The Emeryville, California-based biotechnology company announced the findings in a release carried by the [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-14-prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides).

## How ProLynx's Hydrogel Platform Works

[ProLynx](https://akta.pro/company-profiles/0003au9/prolynx) develops ultra-long-acting medicines for obesity and related metabolic diseases. Its platform tethers peptides to biodegradable hydrogel microspheres through releasable linkers that cleave at a preprogrammed rate, so half-life is governed by release from the depot rather than by the peptide alone.

Most long-acting obesity peptides rely on fatty-acid lipidation, which binds the drug to albumin and generally limits practical half-life to about one week, according to the release. ProLynx said its approach can extend exposure over several months, keep peak concentrations low and preserve weight-loss efficacy comparable to lipidated peptides.

The three posters covered an amylin agonist that sustained 12-week weight loss in diet-induced obese rats after a single dose, a GLP-1/GIP dual agonist that reached a half-life greater than one month without lipidation, and native peptides that delivered the same maximal weight loss as their lipidated counterparts. All three were presented on November 14, 2026, from 7:30 to 8:30 p.m. ET and are available on the [ProLynx website](https://prolynxinc.com).

"Today's obesity medicines have transformed care, but weekly injections and dosing-related side effects remain real barriers to long-term treatment," said Chris Boulton, Chief Executive Officer of ProLynx. "These three presentations show what our platform can do across incretin and amylin biology."

## ProLynx's Funding and Pipeline Records

ProLynx closed a $70 million Series A in December 2025 co-led by 5AM Ventures, OrbiMed and Monograph Capital, with all three partners joining the board, according to akta.pro [company records](https://akta.pro/company-data). The same records show the company advanced PLX-821, an ultra-long-acting semaglutide, as its lead program targeting once-monthly and once-quarterly dosing for obesity and type 2 diabetes, alongside a pipeline of dual and triple agonists, amylin-based therapies and combination approaches. ProLynx is in preclinical development, advancing toward IND enablement and clinical proof-of-concept.

## ProLynx's Leadership Appointments

ProLynx appointed Simon Harnest as Chief Financial Officer and Amer Mirza as Chief Scientific Officer to its leadership team, Investing.com reported in July 2026. Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, placed Mirza as Chief Scientific Officer, Aijourn reported on July 16, 2026.

## What ProLynx Said About Translation

"The overall efficacy of an anti-obesity peptide reflects the interplay between its intrinsic potency and its sustained, steady-state exposure," said Amer Mirza, PhD, Chief Scientific Officer of ProLynx. "Our platform uncouples the two, delivering tunable half-life extension without relying on a lipid tail."

## Companies in this story

- [ProLynx company profile](https://akta.pro/company-profiles/0003au9/prolynx) · website: https://prolynxinc.com

---
News for Agent · https://newsforagent.com/llms.txt